Edge AI Neurostimulation Controllers Versus Continuous Therapy for Drug-Resistant Focal Epilepsy
Edge Computing Artificial Intelligence Neurostimulation Controllers Versus Standard Continuous Therapy for Drug Resistant Focal Epilepsy: A Randomized Controlled Trial
Drug-resistant focal epilepsy remains a major therapeutic challenge. Conventional neurostimulators rely on static, continuous open-loop stimulation or low-bandwidth reactive loops that suffer from classification latency or high battery consumption. This prospective, double-blind, randomized controlled trial evaluates whether hardware-integrated edge computing artificial intelligence (AI) neurostimulators demonstrate superior seizure reduction, lower processing latency, and reduced battery drain compared to standard continuous neurostimulation therapy over a 6-week intervention period.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Eighty adult patients with drug-resistant focal epilepsy undergoing intracranial lead implantation across tertiary referral centers were randomized 1:1 post-implantation into two parallel groups: Edge Computing AI Neurostimulation: Received localized on-hardware machine learning feature extraction and pre-ictal spike classification from intracranial EEG, triggering adaptive targeted high-frequency electrical impulse bursts. Standard Continuous Therapy: Received conventional fixed-frequency, open-loop electrical neurostimulation. The trial evaluated clinical seizure frequency tracked via direct intracortical telemetry logs validated by daily patient diaries, as well as operational hardware metrics including microchip classification latency, real-time inference execution loads, and daily milliampere-hour battery consumption over 6 weeks.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Punjab Province
-
Lahore, Punjab Province, Pakistan, 54570
- Tertiary Neurosurgical Referral Hospitals
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosed with refractory (drug-resistant) focal epilepsy.
- Minimum of four electroclinically documented disabling focal seizures per month despite compliance with two or more appropriately chosen antiseizure medications.
- Scheduled for clinical intracranial lead implantation (subdural grid or depth electrodes).
- Aged 18 to 65 years at the time of enrollment.
Exclusion Criteria:
- Diagnosis of primary generalized epilepsy.
- Progressive neurological disorders.
- Severe cognitive impairment.
- Active psychiatric conditions.
- Previous cranial neurostimulation implants.
- Medical contraindications to surgical implantation or continuous intracortical telemetry.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Edge Computing AI Neurostimulation
Participants received an implantable neurostimulator running local edge computing machine learning algorithms to classify pre-ictal spikes from intracortical EEG in real time, delivering adaptive targeted electrical impulse bursts. |
Hardware-integrated neural processing engine executing real-time feature extraction and pre-ictal spike classification from intracranial EEG, triggering adaptive electrical bursts. |
|
Actieve vergelijker: Standard Continuous Therapy
Participants received continuous open-loop static neurostimulation delivering fixed-frequency electrical pulses regardless of underlying electrical activity. |
Static, fixed-frequency continuous open-loop electrical pulse stimulation delivered regardless of underlying electrical activity. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Monthly Clinical Focal Seizure Frequency
Tijdsspanne: Baseline and Week 6 (completion of intervention)
|
Number of clinical focal seizures per month, recorded continuously via automated direct intracortical telemetry logs and verified against daily patient seizure diaries |
Baseline and Week 6 (completion of intervention)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Microchip Pre-Ictal Classification Latency
Tijdsspanne: Continuously across the 6-week intervention
|
Local on-hardware signal processing and classification response time measured in milliseconds (ms) from raw intracranial EEG pattern identification to trigger execution. |
Continuously across the 6-week intervention
|
|
Daily Battery Drain Rate
Tijdsspanne: Continuously across the 6-week intervention
|
Average daily battery consumption rate measured in milliampere-hours per day (mAh/day) from device telemetry logs. |
Continuously across the 6-week intervention
|
|
Real-Time Microchip Inference Load
Tijdsspanne: Continuously across the 6-week intervention
|
Percentage of microchip processing capacity utilized during real-time on-device machine learning execution. |
Continuously across the 6-week intervention
|
|
Number of Participants with Adverse Events
Tijdsspanne: Throughout the 8-month trial duration
|
Hardware-related, surgical, or neurological adverse events documented throughout the trial. |
Throughout the 8-month trial duration
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Ammar Khalil, University of Kotli
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- UoK1117A
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .